Received Apr 5, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 34HG2 | — |
Pediatric dose administered to adult; Pediatric dose administered to adult; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 47-year-old female patient who received HAV (Havrix 720) (batch number 34HG2, expiry date 12-AUG-2027) for prophylaxis. On 24-MAR-2026, the patient received the 1st dose of Havrix 720 .5 ml. On 24-MAR-2026, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: Pediatric dose administered to adult) and underdose (Verbatim: Pediatric dose administered to adult). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-MAR-2026 The nurse reported that one of their facilities administered a pediatric dose of Havrix to an adult.